KL, Malaysia, March 4, 2025 — Metro Healthcare Bhd (KL:METRO), a leading provider of in vitro fertilisation (IVF) services in Malaysia, is now shifting its focus towards expanding its maternity healthcare business. After establishing itself as the largest network of IVF centres in the country, Metro Healthcare is positioning itself to become a key player in the broader women’s healthcare space, particularly with the increasing demand for maternity care.
Expanding Maternity Services and Long-Term Growth Plans
Dr. Tee Swi Peng, Metro’s founder and executive vice-chairman, revealed in an interview with The Edge that the company’s next growth phase would be in the maternity healthcare sector. Since listing on Bursa Malaysia’s LEAP Market in 2018, Metro has steadily grown its fertility services, and now the company sees a rising demand for maternity care as an essential area for expansion. “We are focusing on maternity centres, and we’re also looking at the possibility of expanding into multidisciplinary hospitals in the long run,” Dr. Tee stated.
Metro’s journey in women’s healthcare began in 1989 with the opening of the Tee Maternity and Gynae Specialist Centre in Klang, Selangor. After venturing into fertility treatment in 1998 under Metro IVF, the company quickly grew its network and now operates 16 OB-GYN facilities, which include three maternity hospitals, six fertility centres, six women’s health clinics, and one diagnostic imaging centre.
New Acquisition and Increased Capacity
As part of this expansion, Metro recently acquired a four-storey shop-office in Subang Jaya, Selangor, for RM9.5 million. This property, previously tenanted by Quality Health Care Sdn Bhd, which operates a 10-bed maternity hospital, will allow Metro to expand its maternity centre to 40 beds, up from the current 30. Metro is actively seeking similar opportunities to grow its network of maternity centres, with a focus on accessible locations to serve pregnant women who make frequent visits during their pregnancies.
Dr. Tee explained, “When it comes to maternity centres, the most important factors are safety and accessibility. Pregnant women typically make at least 10 visits during pregnancy, so we aim to cover as much area as possible, targeting the middle 40% (M40) income segment.” The company’s existing maternity centres are located in Klang, Banting, and Kuala Selangor, with additional clinics in Cheras, Old Klang Road, Seremban, and Puchong.
Expansion Plans for Fertility Services
In addition to maternity care, Metro Healthcare is also investing in expanding its fertility services, with both domestic and international growth in the pipeline. The group currently operates six IVF centres across key Malaysian states including Selangor, Johor, Melaka, and Penang. Metro is looking to expand its network to eight centres, with new locations opening in Ipoh, Perak, and Kelantan later this year.
Metro’s IVF services are gaining recognition beyond Malaysia’s borders, with patients from countries like the UK, Australia, Singapore, Indonesia, and China seeking fertility treatment in Malaysia. Dr. Tee noted, “Our IVF treatment is among the best in the region and is affordable, which has made Malaysia a sought-after destination for fertility services.”
The company is also planning to open satellite IVF centres in China and Indonesia by the end of 2025, tapping into these rapidly growing markets before local competition intensifies. As fertility technology evolves quickly, Dr. Tee emphasized that Metro must act quickly to capture these opportunities.
Advanced Technology and High Success Rates
Metro’s IVF services are enhanced by advanced technology, including the newly introduced preimplantation genetic testing (PGT), which screens embryos for genetic abnormalities before implantation. Previously, Metro had sent patients abroad for this service but now offers it in-house with cutting-edge equipment.
Metro’s IVF treatment boasts a success rate of 70%, which can increase to 90% with advanced treatment options. This, combined with its expanding network, positions the company well for both domestic growth and international expansion.
Financial Performance and Future Prospects
In FY2023, Metro reported a net profit of RM6.25 million on revenue of RM44.69 million, with a net profit margin of 14%. The majority of the revenue came from the maternity centres and clinics (55.15%), followed by the fertility services (43.36%).
Metro is also planning further acquisitions to support its long-term growth strategy in both the maternity and fertility healthcare sectors. The group raised RM39.2 million through its ACE Market listing last November, with RM25 million allocated for expansion purposes.
Conclusion: A Strategic Focus on Women’s Healthcare
Metro Healthcare’s expansion strategy reflects the increasing demand for comprehensive women’s healthcare services, including both fertility and maternity care. The company’s commitment to improving accessibility and the quality of care, along with its continued investment in advanced medical technology, positions it to remain a leader in Malaysia’s healthcare sector. As Metro continues to expand, it is poised to shape the future of fertility and maternity care, both locally and internationally.
Related topics:
Aayat IVF and Infertility Centre Inaugurated in Ahmedabad to Offer Advanced Fertility Treatments
Trump’s IVF Executive Order Misses the Mark in Addressing America’s Fertility Crisis
Infertility and Intimacy Issues: How Relationship Struggles Affect Conception in Today’s World
